Insider Selling: Mesa Laboratories, Inc. (NASDAQ:MLAB) SVP Sells 1,499 Shares of Stock

Mesa Laboratories, Inc. (NASDAQ:MLAB) SVP Brian David Archbold sold 1,499 shares of the firm’s stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $125.00, for a total transaction of $187,375.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Mesa Laboratories Trading Down 2.0 %

Mesa Laboratories stock traded down $2.46 during trading hours on Monday, reaching $123.25. 13,070 shares of the company’s stock traded hands, compared to its average volume of 43,404. The firm has a market capitalization of $666.78 million, a price-to-earnings ratio of -2.67 and a beta of 0.85. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.37 and a current ratio of 1.94. Mesa Laboratories, Inc. has a fifty-two week low of $82.86 and a fifty-two week high of $141.17. The firm’s 50 day moving average is $118.18 and its 200-day moving average is $109.18.

Mesa Laboratories (NASDAQ:MLAB) last posted its quarterly earnings results on Monday, August 5th. The medical instruments supplier reported $2.29 earnings per share for the quarter, topping analysts’ consensus estimates of $1.74 by $0.55. Mesa Laboratories had a negative net margin of 111.89% and a positive return on equity of 18.95%. The business had revenue of $58.17 million during the quarter, compared to the consensus estimate of $55.90 million. On average, analysts predict that Mesa Laboratories, Inc. will post 7.91 earnings per share for the current year.

Mesa Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, September 16th. Stockholders of record on Friday, August 30th will be given a $0.16 dividend. The ex-dividend date of this dividend is Friday, August 30th. This represents a $0.64 annualized dividend and a dividend yield of 0.52%. Mesa Laboratories’s dividend payout ratio is currently -1.36%.

Analysts Set New Price Targets

MLAB has been the topic of several research analyst reports. Evercore ISI increased their price target on shares of Mesa Laboratories from $106.00 to $120.00 and gave the company an “outperform” rating in a research note on Tuesday, August 6th. Wells Fargo & Company began coverage on Mesa Laboratories in a research note on Tuesday, August 27th. They issued an “underweight” rating and a $120.00 target price for the company.

Institutional Investors Weigh In On Mesa Laboratories

A number of institutional investors have recently made changes to their positions in the stock. Canada Pension Plan Investment Board acquired a new position in Mesa Laboratories during the second quarter valued at approximately $26,000. Quadrant Capital Group LLC boosted its position in shares of Mesa Laboratories by 515.6% during the fourth quarter. Quadrant Capital Group LLC now owns 277 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 232 shares in the last quarter. EntryPoint Capital LLC grew its holdings in shares of Mesa Laboratories by 35.2% in the 1st quarter. EntryPoint Capital LLC now owns 741 shares of the medical instruments supplier’s stock valued at $81,000 after buying an additional 193 shares during the period. Sanctuary Advisors LLC bought a new stake in shares of Mesa Laboratories in the 2nd quarter valued at $183,000. Finally, Louisiana State Employees Retirement System increased its position in shares of Mesa Laboratories by 4.0% in the 2nd quarter. Louisiana State Employees Retirement System now owns 2,600 shares of the medical instruments supplier’s stock valued at $226,000 after buying an additional 100 shares in the last quarter. 90.60% of the stock is owned by institutional investors and hedge funds.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc develops, manufactures, and sells life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. It operates in four segments: Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions.